Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCITestCare: Stem Cell and BCI for Mild Cognitive Impairment
NCT07214974Phase 1Not yet recruiting
- Sponsor
- DR.NOAH BIOTECH
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Mild Cognitive Impairment (MCI) (4 arms), sponsored by DR.NOAH BIOTECH. Primary endpoints: Montreal Cognitive Assessment at 5 years and Rate of Progression to Dementia at 5 years. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07214974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214974.